Articles

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas

University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
Oregon Health and Science University, Portland, OR, USA;
University of Pennsylvania, Philadelphia, PA, USA;
Fox Chase Cancer Center, Philadelphia, PA, USA;
Thomas Jefferson University, Philadelphia, PA, USA;
Thomas Jefferson University, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
Centre for Lymphoid Cancer, Vancouver, BC, Canada
Centre for Lymphoid Cancer, Vancouver, BC, Canada
Fox Chase Cancer Center, Philadelphia, PA, USA;
Centre for Lymphoid Cancer, Vancouver, BC, Canada
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
University of Pennsylvania, Philadelphia, PA, USA;
Haematologica Early view May 15, 2020 https://doi.org/10.3324/haematol.2019.238675